Showing results (211-220 of 230) with videos related to

Sort By:
Pageof 23
Circulation|October 25, 2006
Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation studyTerje K Steigen, Michael Maeng, Rune Wiseth, et al.
Journal of the American College of Cardiology|October 7, 2004
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trialPatrick W Serruys, John A Ormiston, Georgios Sianos, et al.
JAMA|January 31, 2008
Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trialAnders M Galløe, Leif Thuesen, Henning Kelbaek, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Sex-Specific Clinical Outcomes After Treatment of Left Main Coronary Artery Disease. A NOBLE SubstudyMargaret B McEntegart, Niels R Holm, Martin M Lindsay, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 1, 2013
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trialsBill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, et al.
European Heart Journal|May 11, 2016
Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary StudyMiles W Behan, Niels R Holm, Adam J de Belder, et al.
Lancet (London, England)|March 17, 2010
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trialKlaus Rasmussen, Michael Maeng, Anne Kaltoft, et al.
JACC. Cardiovascular Interventions|June 23, 2012
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trialBill D Gogas, Patrick W Serruys, Roberto Diletti, et al.
Heart (British Cardiac Society)|November 3, 2012
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trialRoberto Diletti, Vasim Farooq, Chrysafios Girasis, et al.
Lancet (London, England)|April 5, 2026
Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trialEmil Nielsen Holck, Niels R Holm, David Hildick-Smith, et al.
Pageof 23